Format

Send to

Choose Destination
ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Author information

1
NIHR Southampton Respiratory Biomedical Research Centre University Hospital Southampton and Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
2
ILD Unit, Royal Brompton Hospital, London, UK.
3
Papworth Hospital, Cambridge, UK.
4
John Radcliffe Hospital, Oxford, UK.
5
Queen Alexandra Hospital, Portsmouth, UK.
6
Aintree University Hospital, Liverpool, UK.

Abstract

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67.

Conflict of interest statement

Conflict of interest: S.V. Fletcher reports receiving funding to attend conferences, speaker fees and fees for advisory boards from Roche and Boehringer Ingelheim. Conflict of interest: M.G. Jones has nothing to disclose. Conflict of interest: E.A. Renzoni reports receiving lecture fees from Boehringer, Roche and Takeda outside the submitted work. Conflict of interest: H. Parfrey reports receiving personal fees for consultancy work from Boehringer Ingelheim and Roche, and nonfinancial support for conference attendance from Boehringer Ingelheim and Roche. Conflict of interest: R.K. Hoyles reports receiving support for a specialist interstitial lung disease nurse (part time) for 1 year outside the submitted work. Conflict of interest: K. Spinks reports receiving advisory board fees and conference sponsorship from Boehringer Ingelheim, and educational meeting sponsorship from Roche, outside the submitted work. Conflict of interest: M. Kokosi has nothing to disclose. Conflict of interest: A. Kwok has nothing to disclose. Conflict of interest: C. Warburton has nothing to disclose. Conflict of interest: V. Titmuss reports receiving personal fees for discussion on the new formulary of pirfenidone and its new patient information leaflet from the Roche Nurse Advisory Board outside the submitted work. Conflict of interest: M. Thillai has received travel scholarships and consultancy fees from Boehringer Ingelheim and Roche. Conflict of interest: N. Simler has nothing to disclose. Conflict of interest: T.M. Maher reports receiving grant funding to his institution and personal fees for service on a clinical trial advisory board from GSK; personal fees from Boehringer Ingelheim, InterMune, Sanofi Aventis, AstraZeneca, Roche, Biogen Idec, Cipla, Prometic and Sanumed; research fees to his institution, personal fees and nonfinancial support from UCB; and holds stock options in Apellis, all outside the submitted work. Conflict of interest: C.J. Brereton reports receiving support to attend a conference from Boehringer Ingelheim outside the submitted work. Conflict of interest: F. Chua has nothing to disclose. Conflict of interest: A.U. Wells reports receiving fees for consulting and speaking from Intermune/Roche, Boehringer Ingelheim and Bayer, fees for consulting from Gilead, outside the submitted work. Conflict of interest: L. Richeldi reports grants and personal fees for service on an advisory board from InterMune, personal fees for service on an advisory board from Medimmune, Roche and FibroGen, personal fees for consulting activity from Biogen, Sanofi-Aventis, ImmuneWorks, Celgene and Nitton, a speaker fee from Shionogi, and personal fees for service on a steering committee from Boehringer Ingelheim, outside the submitted work. Conflict of interest: L.G. Spencer has received payments for advisory boards and travel support to attend respiratory conferences from both Boehringer Ingelheim and Roche, and speaker fees from Boehringer Ingelheim in the last 36 months.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center